Champions Oncology (CSBR) Change in Receivables (2013 - 2026)
Champions Oncology (CSBR) posted quarterly Change in Receivables of $1.2 million for Q2 2026, up 126.33% year-over-year from $523564.1 in Q2 2025, and up 137.95% quarter-over-quarter from $498000.0 in Q1 2026.
Champions Oncology (CSBR) Change in Receivables (2013 - 2026) Analysis & Trends
Champions Oncology's Change in Receivables history runs 14 years deep, the most recent figure standing at $1.2 million for Q2 2026.
- In Q2 2026, Change in Receivables rose 126.33% year-over-year to $1.2 million; the TTM figure through Apr 2026 stood at $2.0 million (up 39.42% YoY), while the FY2026 annual figure was $2.0 million, up 39.42% from the prior year.
- Change in Receivables for Q2 2026 stood at $1.2 million, up from $498000.0 in the prior quarter.
- The five-year high for Change in Receivables was $5.3 million in Q1 2025, with the low at -$4.5 million in Q2 2025.
- The 5-year median for Change in Receivables is $311000.0 (2022), against an average of $312111.1.
- The sharpest annual moves came in 2023 and 2024: Change in Receivables plunged 353.49% in 2023, then soared 2500.0% in 2024.
- Champions Oncology's Change in Receivables stood at -$276000.0 in 2022, then tumbled by 317.39% to -$1.2 million in 2023, then jumped by 206.68% to $1.2 million in 2024, then jumped by 69.08% to $2.1 million in 2025, then tumbled by 42.97% to $1.2 million in 2026.
- Business Quant data shows CSBR's Change in Receivables at $1.2 million in Q2 2026, $498000.0 in Q1 2026, and $2.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Champions Oncology | 68.61 Mn | 68.61 Mn | 7.03 Mn | 1.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 1.19 Mn |
| Apr 30, 2026 | 1.19 Mn |
| Jan 31, 2026 | 498,000.00 |
| Jan 31, 2026 | 498,000.00 |
| Oct 31, 2025 | 2.08 Mn |
| Oct 31, 2025 | 2.08 Mn |
| Jul 31, 2025 | -1.76 Mn |
| Jul 31, 2025 | -1.76 Mn |
| Apr 30, 2025 | -4.50 Mn |
| Apr 30, 2025 | -4.50 Mn |
| Jan 31, 2025 | 5.27 Mn |
| Jan 31, 2025 | 5.27 Mn |
| Oct 31, 2024 | 1.23 Mn |
| Oct 31, 2024 | 1.23 Mn |
| Jul 31, 2024 | -565,000.00 |
| Jul 31, 2024 | -565,000.00 |
| Apr 30, 2024 | 1.79 Mn |
| Apr 30, 2024 | 1.79 Mn |
| Jan 31, 2024 | 250,000.00 |
| Jan 31, 2024 | 250,000.00 |